ID   ASGL1_HUMAN             Reviewed;         308 AA.
AC   Q7L266; B2R7Q0; Q567Q4; Q6P1P0; Q8NI34; Q9H6F7;
DT   02-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 2.
DT   15-MAR-2017, entry version 121.
DE   RecName: Full=Isoaspartyl peptidase/L-asparaginase;
DE            EC=3.4.19.5 {ECO:0000269|PubMed:19839645};
DE            EC=3.5.1.1 {ECO:0000269|PubMed:19839645, ECO:0000269|PubMed:22891768};
DE   AltName: Full=Asparaginase-like protein 1 {ECO:0000303|PubMed:19839645};
DE   AltName: Full=Beta-aspartyl-peptidase {ECO:0000303|PubMed:19839645};
DE   AltName: Full=Isoaspartyl dipeptidase;
DE   AltName: Full=L-asparagine amidohydrolase;
DE   Contains:
DE     RecName: Full=Isoaspartyl peptidase/L-asparaginase alpha chain;
DE   Contains:
DE     RecName: Full=Isoaspartyl peptidase/L-asparaginase beta chain;
DE   Flags: Precursor;
GN   Name=ASRGL1; Synonyms=ALP, CRASH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Testis;
RX   PubMed=11984834; DOI=10.1002/mrd.10092;
RA   Bush L.A., Herr J.C., Wolkowicz M., Sherman N.E., Shore A.,
RA   Flickinger C.J.;
RT   "A novel asparaginase-like protein is a sperm autoantigen in rats.";
RL   Mol. Reprod. Dev. 62:233-247(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RX   PubMed=14654938;
RA   Evtimova V., Zeillinger R., Kaul S., Weidle U.H.;
RT   "Identification of CRASH, a gene deregulated in gynecological
RT   tumors.";
RL   Int. J. Oncol. 24:33-41(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Corpus callosum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Eye, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVE
RP   SITE, MUTAGENESIS OF THR-168, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   AUTOCATALYTIC CLEAVAGE.
RX   PubMed=19839645; DOI=10.1021/bi901397h;
RA   Cantor J.R., Stone E.M., Chantranupong L., Georgiou G.;
RT   "The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase
RT   with beta-aspartyl peptidase activity.";
RL   Biochemistry 48:11026-11031(2009).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEXES WITH ASPARTATE,
RP   ACTIVE SITE, SUBUNIT, ENZYME REGULATION, AND AUTOCATALYTIC CLEAVAGE.
RX   PubMed=22861376; DOI=10.1021/bi300870g;
RA   Nomme J., Su Y., Konrad M., Lavie A.;
RT   "Structures of apo and product-bound human L-asparaginase: insights
RT   into the mechanism of autoproteolysis and substrate hydrolysis.";
RL   Biochemistry 51:6816-6826(2012).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS), CATALYTIC ACTIVITY, MUTAGENESIS
RP   OF THR-168, AND SUBUNIT.
RX   PubMed=22891768; DOI=10.1021/cb300232n;
RA   Li W., Cantor J.R., Yogesha S.D., Yang S., Chantranupong L., Liu J.Q.,
RA   Agnello G., Georgiou G., Stone E.M., Zhang Y.;
RT   "Uncoupling intramolecular processing and substrate hydrolysis in the
RT   N-terminal nucleophile hydrolase hASRGL1 by circular permutation.";
RL   ACS Chem. Biol. 7:1840-1847(2012).
CC   -!- FUNCTION: Has both L-asparaginase and beta-aspartyl peptidase
CC       activity. May be involved in the production of L-aspartate, which
CC       can act as an excitatory neurotransmitter in some brain regions.
CC       Is highly active with L-Asp beta-methyl ester. Besides, has
CC       catalytic activity toward beta-aspartyl dipeptides and their
CC       methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl
CC       ester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L-
CC       Asp-L-Lys. Does not have aspartylglucosaminidase activity and is
CC       inactive toward GlcNAc-L-Asn. Likewise, has no activity toward
CC       glutamine. {ECO:0000269|PubMed:19839645}.
CC   -!- CATALYTIC ACTIVITY: L-asparagine + H(2)O = L-aspartate + NH(3).
CC       {ECO:0000269|PubMed:19839645, ECO:0000269|PubMed:22891768}.
CC   -!- CATALYTIC ACTIVITY: Cleavage of a beta-linked Asp residue from the
CC       N-terminus of a polypeptide. {ECO:0000269|PubMed:19839645}.
CC   -!- ENZYME REGULATION: Glycine accelerates autocleavage into an alpha
CC       and beta chain. {ECO:0000269|PubMed:22861376}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.4 mM for L-asparagine (L-Asn)
CC         {ECO:0000269|PubMed:19839645};
CC         KM=0.4 mM for L-aspartic acid beta-methyl ester
CC         {ECO:0000269|PubMed:19839645};
CC         KM=0.4 mM for L-Asp-L-Phe {ECO:0000269|PubMed:19839645};
CC         KM=1.0 mM for L-Asp-L-Ala {ECO:0000269|PubMed:19839645};
CC   -!- SUBUNIT: Heterodimer of an alpha and beta chain produced by
CC       autocleavage. This heterodimer may then dimerize in turn, giving
CC       rise to a heterotetramer. {ECO:0000269|PubMed:22861376,
CC       ECO:0000269|PubMed:22891768}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11984834}.
CC       Note=Midpiece of sperm tail.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q7L266-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7L266-2; Sequence=VSP_028287;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney, testis and tissues
CC       of the gastrointestinal tract. Present in sperm (at protein
CC       level). Over-expressed in uterine, mammary, prostatic and ovarian
CC       carcinoma. {ECO:0000269|PubMed:11984834,
CC       ECO:0000269|PubMed:14654938}.
CC   -!- INDUCTION: By 5-alpha-di-hydrotestosterone and progesterone.
CC       {ECO:0000269|PubMed:14654938}.
CC   -!- PTM: Cleaved into an alpha and beta chain by autocatalysis; this
CC       activates the enzyme. The N-terminal residue of the beta subunit
CC       is responsible for the nucleophile hydrolase activity.
CC       {ECO:0000269|PubMed:19839645, ECO:0000269|PubMed:22861376}.
CC   -!- SIMILARITY: Belongs to the Ntn-hydrolase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15302.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15302.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF411076; AAM28434.1; -; mRNA.
DR   EMBL; AK025969; BAB15302.1; ALT_INIT; mRNA.
DR   EMBL; AK091894; BAG52437.1; -; mRNA.
DR   EMBL; AK313069; BAG35897.1; -; mRNA.
DR   EMBL; CH471076; EAW74012.1; -; Genomic_DNA.
DR   EMBL; BC021295; AAH21295.3; -; mRNA.
DR   EMBL; BC064963; AAH64963.1; -; mRNA.
DR   EMBL; BC093070; AAH93070.1; -; mRNA.
DR   CCDS; CCDS8019.1; -. [Q7L266-1]
DR   RefSeq; NP_001077395.1; NM_001083926.1. [Q7L266-1]
DR   RefSeq; NP_079356.3; NM_025080.3. [Q7L266-1]
DR   RefSeq; XP_005274362.1; XM_005274305.3. [Q7L266-2]
DR   RefSeq; XP_005274363.1; XM_005274306.2. [Q7L266-2]
DR   UniGene; Hs.535326; -.
DR   PDB; 3TKJ; X-ray; 2.30 A; A/B=2-308.
DR   PDB; 4ET0; X-ray; 3.30 A; A/B=2-308.
DR   PDB; 4O0C; X-ray; 1.50 A; A/B=1-308.
DR   PDB; 4O0D; X-ray; 1.95 A; A/B=1-308.
DR   PDB; 4O0E; X-ray; 1.71 A; A/B=1-308.
DR   PDB; 4O0F; X-ray; 1.92 A; A/B=1-308.
DR   PDB; 4O0G; X-ray; 2.10 A; A/B=1-308.
DR   PDB; 4O0H; X-ray; 1.97 A; A/B=1-308.
DR   PDB; 4OSX; X-ray; 1.95 A; A/B=1-308.
DR   PDB; 4OSY; X-ray; 1.91 A; A/B=1-308.
DR   PDB; 4PVP; X-ray; 1.85 A; A/B=1-308.
DR   PDB; 4PVQ; X-ray; 2.13 A; A/B=1-308.
DR   PDB; 4PVR; X-ray; 1.75 A; A/B=1-308.
DR   PDB; 4PVS; X-ray; 1.84 A; A/B=1-308.
DR   PDB; 4ZM9; X-ray; 2.51 A; A/B/C/D=2-308.
DR   PDBsum; 3TKJ; -.
DR   PDBsum; 4ET0; -.
DR   PDBsum; 4O0C; -.
DR   PDBsum; 4O0D; -.
DR   PDBsum; 4O0E; -.
DR   PDBsum; 4O0F; -.
DR   PDBsum; 4O0G; -.
DR   PDBsum; 4O0H; -.
DR   PDBsum; 4OSX; -.
DR   PDBsum; 4OSY; -.
DR   PDBsum; 4PVP; -.
DR   PDBsum; 4PVQ; -.
DR   PDBsum; 4PVR; -.
DR   PDBsum; 4PVS; -.
DR   PDBsum; 4ZM9; -.
DR   ProteinModelPortal; Q7L266; -.
DR   SMR; Q7L266; -.
DR   BioGrid; 123142; 6.
DR   IntAct; Q7L266; 4.
DR   STRING; 9606.ENSP00000301776; -.
DR   DrugBank; DB00174; L-Asparagine.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   iPTMnet; Q7L266; -.
DR   PhosphoSitePlus; Q7L266; -.
DR   BioMuta; ASRGL1; -.
DR   DMDM; 158706477; -.
DR   UCD-2DPAGE; Q7L266; -.
DR   EPD; Q7L266; -.
DR   MaxQB; Q7L266; -.
DR   PaxDb; Q7L266; -.
DR   PeptideAtlas; Q7L266; -.
DR   PRIDE; Q7L266; -.
DR   DNASU; 80150; -.
DR   Ensembl; ENST00000301776; ENSP00000301776; ENSG00000162174. [Q7L266-1]
DR   Ensembl; ENST00000415229; ENSP00000400057; ENSG00000162174. [Q7L266-1]
DR   GeneID; 80150; -.
DR   KEGG; hsa:80150; -.
DR   UCSC; uc001nte.5; human. [Q7L266-1]
DR   CTD; 80150; -.
DR   DisGeNET; 80150; -.
DR   GeneCards; ASRGL1; -.
DR   HGNC; HGNC:16448; ASRGL1.
DR   HPA; CAB070192; -.
DR   HPA; HPA029725; -.
DR   HPA; HPA055572; -.
DR   MIM; 609212; gene.
DR   neXtProt; NX_Q7L266; -.
DR   OpenTargets; ENSG00000162174; -.
DR   PharmGKB; PA25059; -.
DR   eggNOG; KOG1592; Eukaryota.
DR   eggNOG; COG1446; LUCA.
DR   GeneTree; ENSGT00530000063034; -.
DR   HOGENOM; HOG000174613; -.
DR   HOVERGEN; HBG101662; -.
DR   InParanoid; Q7L266; -.
DR   KO; K13051; -.
DR   OMA; PCVGAGG; -.
DR   OrthoDB; EOG091G0CKQ; -.
DR   PhylomeDB; Q7L266; -.
DR   TreeFam; TF323960; -.
DR   BioCyc; MetaCyc:HS08648-MONOMER; -.
DR   BRENDA; 3.4.19.5; 2681.
DR   Reactome; R-HSA-71182; Phenylalanine and tyrosine catabolism.
DR   ChiTaRS; ASRGL1; human.
DR   GeneWiki; ASRGL1; -.
DR   GenomeRNAi; 80150; -.
DR   PRO; PR:Q7L266; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000162174; -.
DR   CleanEx; HS_ASRGL1; -.
DR   ExpressionAtlas; Q7L266; baseline and differential.
DR   Genevisible; Q7L266; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0004067; F:asparaginase activity; IDA:UniProtKB.
DR   GO; GO:0008798; F:beta-aspartyl-peptidase activity; IDA:UniProtKB.
DR   GO; GO:0033345; P:asparagine catabolic process via L-aspartate; IDA:UniProtKB.
DR   GO; GO:0006559; P:L-phenylalanine catabolic process; TAS:Reactome.
DR   CDD; cd04702; ASRGL1_like; 1.
DR   InterPro; IPR033844; ASRGL1_meta.
DR   InterPro; IPR029055; Ntn_hydrolases_N.
DR   InterPro; IPR000246; Peptidase_T2.
DR   PANTHER; PTHR10188; PTHR10188; 1.
DR   Pfam; PF01112; Asparaginase_2; 1.
DR   SUPFAM; SSF56235; SSF56235; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Autocatalytic cleavage; Complete proteome; Cytoplasm; Hydrolase;
KW   Protease; Reference proteome.
FT   CHAIN         1    167       Isoaspartyl peptidase/L-asparaginase
FT                                alpha chain.
FT                                /FTId=PRO_0000305204.
FT   CHAIN       168    308       Isoaspartyl peptidase/L-asparaginase beta
FT                                chain.
FT                                /FTId=PRO_0000420556.
FT   REGION      196    199       Substrate binding.
FT   REGION      219    222       Substrate binding.
FT   ACT_SITE    168    168       Nucleophile.
FT                                {ECO:0000269|PubMed:19839645,
FT                                ECO:0000269|PubMed:22861376}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   VAR_SEQ       1    128       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_028287.
FT   MUTAGEN     168    168       T->A,C: Abolishes activation by
FT                                autocleavage. Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:19839645,
FT                                ECO:0000269|PubMed:22891768}.
FT   MUTAGEN     168    168       T->S: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:19839645,
FT                                ECO:0000269|PubMed:22891768}.
FT   CONFLICT    181    181       A -> T (in Ref. 1; AAM28434).
FT                                {ECO:0000305}.
FT   STRAND        4      8       {ECO:0000244|PDB:4O0C}.
FT   HELIX        17     38       {ECO:0000244|PDB:4O0C}.
FT   TURN         39     41       {ECO:0000244|PDB:4O0C}.
FT   HELIX        44     57       {ECO:0000244|PDB:4O0C}.
FT   STRAND       61     64       {ECO:0000244|PDB:4O0C}.
FT   STRAND       71     73       {ECO:0000244|PDB:4O0H}.
FT   STRAND       77     83       {ECO:0000244|PDB:4O0C}.
FT   TURN         84     86       {ECO:0000244|PDB:4O0C}.
FT   STRAND       89     95       {ECO:0000244|PDB:4O0C}.
FT   HELIX       101    111       {ECO:0000244|PDB:4O0C}.
FT   STRAND      115    118       {ECO:0000244|PDB:4O0C}.
FT   HELIX       119    128       {ECO:0000244|PDB:4O0C}.
FT   HELIX       136    138       {ECO:0000244|PDB:4O0C}.
FT   HELIX       142    152       {ECO:0000244|PDB:4O0C}.
FT   STRAND      169    174       {ECO:0000244|PDB:4O0C}.
FT   STRAND      180    186       {ECO:0000244|PDB:4O0C}.
FT   TURN        203    205       {ECO:0000244|PDB:4O0C}.
FT   STRAND      206    210       {ECO:0000244|PDB:4O0C}.
FT   TURN        211    213       {ECO:0000244|PDB:4O0C}.
FT   STRAND      214    220       {ECO:0000244|PDB:4O0C}.
FT   HELIX       222    228       {ECO:0000244|PDB:4O0C}.
FT   HELIX       230    239       {ECO:0000244|PDB:4O0C}.
FT   HELIX       244    259       {ECO:0000244|PDB:4O0C}.
FT   STRAND      263    269       {ECO:0000244|PDB:4O0C}.
FT   STRAND      274    282       {ECO:0000244|PDB:4O0C}.
FT   STRAND      285    289       {ECO:0000244|PDB:4O0C}.
FT   STRAND      292    298       {ECO:0000244|PDB:4O0C}.
FT   STRAND      303    306       {ECO:0000244|PDB:4O0C}.
SQ   SEQUENCE   308 AA;  32055 MW;  84E3D6C2D1555B32 CRC64;
     MNPIVVVHGG GAGPISKDRK ERVHQGMVRA ATVGYGILRE GGSAVDAVEG AVVALEDDPE
     FNAGCGSVLN TNGEVEMDAS IMDGKDLSAG AVSAVQCIAN PIKLARLVME KTPHCFLTDQ
     GAAQFAAAMG VPEIPGEKLV TERNKKRLEK EKHEKGAQKT DCQKNLGTVG AVALDCKGNV
     AYATSTGGIV NKMVGRVGDS PCLGAGGYAD NDIGAVSTTG HGESILKVNL ARLTLFHIEQ
     GKTVEEAADL SLGYMKSRVK GLGGLIVVSK TGDWVAKWTS TSMPWAAAKD GKLHFGIDPD
     DTTITDLP
//
